CHR Hansen Q1 Report 2022
Q1 2021/22 highlights
- Revenue amounted to EUR 268 million, up 10% from EUR 243 million in Q1 2020/21.
- Organic growth was 9% driven by volume growth. The Lighthouses (Bioprotection, Fermented Plant Bases, Plant Health and HMO) delivered 35% organic growth combined, while the remaining Core businesses delivered 7% organic growth.
- Food Cultures & Enzymes organic growth was 7% driven by volume.
- Health & Nutrition organic growth was 13% driven by volume.
- The EBIT margin b.s.i. was 24.4%, down from 25.2% in Q1 2020/21. Production efficiencies and scalability effects from the solid sales performance were offset by higher input costs not yet reflected in the sales prices, a general ramp- up of activities including travel, and the full inclusion of HMO.
- Implementation of price adjustments to reflect the current inflationary pressure is progressing as planned in close collaboration with our customers and is expected to have an effect from Q2 onwards.
- Bacthera entered into an agreement with Seres Therapeutics for the commercial manufacturing of SER-109, a
potential treatment against recurrent C. difficile infection.
Q1 2021/22 revenue amounted to EUR 268 million, up 10% from EUR 243 million in Q1 2020/21. Revenue was positively impacted by 1% from currency effects and a small impact from acquisitions as the Jennewein acquisition was closed on October 9, 2020.
Organic growth was 9% supported by strong growth from Health & Nutrition and solid growth from Food Cultures &
Enzymes. The improvement was driven by volume growth with no contribution from pricing. Implementation of price adjustments to reflect the current inflationary pressure is progressing as planned in close collaboration with our customers with an expected effect from Q2 onwards.
